Leukemia/Lymphoma/Hematologic

SS 35 - Hematologic 3 -?Translating Better Technology to Improved Outcome in Primary and Relapsed Disease

254 - Long-term Outcome of Involved Node Radiation Therapy for Early Stage Hodgkin Lymphoma

Wednesday, October 24
8:15 AM - 8:25 AM
Location: Room 007 A/B

Long-term Outcome of Involved Node Radiation Therapy for Early Stage Hodgkin Lymphoma
K. Nielsen1, M. V. Maraldo1, M. C. Aznar2, P. M. Petersen1, I. Vogelius1, and L. Specht1; 1Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 2Manchester Cancer Research Center, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom

Purpose/Objective(s): Involved node radiation therapy (INRT) in the combined modality treatment (CMT) of early stage Hodgkin lymphoma (ESHL) has dramatically reduced the irradiated volume thereby reducing the risk of late effects. Here we present the long-term outcome of this treatment in a cohort of ESHL patients.

Materials/Methods: Updated results of CMT including INRT in a cohort of 97 patients with classical ESHL treated from 2005 until 2010 were collected from national registries. Overall survival (OS), progression free survival (PFS), defined as time from date of diagnosis to progression or death of any cause, and time to progression (TTP) used as a measure to evaluate tumor control and defined as time from date of diagnosis to progression or death due to HL, were calculated using the Kaplan-Meier method.

Results: Patient characteristics are shown in Table 1. Median follow-up time for patients still alive was 126 months (range: 10–160). Four patients were lost to follow up due to emigration abroad (2) or to North Atlantic territory (2). Seven patients relapsed (crude relapse rate: 7.2%) after a median of 36 months (range: 7-113), three in initially involved and irradiated nodes, four in initially uninvolved and not irradiated nodes. A total of 17 patients died, none from HL. 5- and 10-year Kaplan-Meier data were: OS: 90.6% (95% CI: 84.7-96.5) and 83.6% (95% CI: 76.0-91.2); PFS: 86.4% (95% CI: 79.3-93.5) and 76.7% (95% CI: 67.9-85.5); TTP: 94.6% (95% CI: 90.1-99.1) and 91.4% (95% CI: 85.1-97.7). 23 serious late events occurred, of which 12 were malignancies, three lymphomas (mucosa-associated lymphoid tissue, small lymphocytic lymphoma, angioimmunoblastic T-cell lymphoma) and nine solid tumors (two breast, one each of colon, lung, prostate, kidney, endometrial, melanoma) and 11 were cardiac events, four ischaemic, five atrial flutter, one Wolff-Parkinson-White syndrome and one valvular. Another 63 minor events possibly related to treatment were reported, hypothyroidism (13.4%) and reduced lung capacity (12.4%) were the most frequent.
Table 1. Patients n (%)
No. of patients 97
Gender Men 50 (51.6)
Women 47 (48.4)
Age, y, median range 36 (15-87)
Chemotherapy ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) 90 (92.8)
Other 7 (7.2)
Radiation therapy With boost (to 36 Gy) 71 (73.2)
Without boost (30.6 Gy) 26 (26.8)

Conclusion: CMT including INRT provides excellent local lymphoma control in patients with ESHL and maintains the high survival rates with more than 10 years of follow-up. Further analyses of the observed late events and their relation to chemo- or radiation therapy are ongoing.

Author Disclosure: K. Nielsen: None. M.V. Maraldo: None. P.M. Petersen: None. I. Vogelius: Research Grant; Viewray, Varian Medical System. L. Specht: Research Grant; Varian. Honoraria; Takeda. Consultant; Takeda. Advisory Board; Takeda, MSD. Travel Expenses; Merck Serono, Takeda. Vice President; International Lymphoma Radiation Oncology Group.

Karin Nielsen, MD

Disclosure:
Employment
Rigshospitalet, University of Copenhagen: MD, PhD-student: Employee

Presentation(s):

Send Email for Karin Nielsen


Assets

254 - Long-term Outcome of Involved Node Radiation Therapy for Early Stage Hodgkin Lymphoma



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Long-term Outcome of Involved Node Radiation Therapy for Early Stage Hodgkin Lymphoma